North America TB Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing (NAT), Skin Test / Mantoux Test (TST), Blood Test / Serology Test, SMEAR Microscopy, Cultured-Based Tests, Radiography Tests, Others), By End-User (Hospitals and Diagnostic Laboratories, Physician’s Office Laboratories, Reference Laboratories, Academics and Research Facilities) and By Country (US, Canada) Forecasts, 2026-2034

North America TB Diagnostics Market Size

The North America TB diagnostics market size was valued at USD 474 million in 2025 and is projected to reach USD 505.28 million in 2026 and USD 842.55 million by 2034, growing at a CAGR of 6.6% during the forecast period 2026-2034.

Tuberculosis (TB) is an infectious illness caused by Mycobacterium tuberculosis bacteria (MTB). Tuberculosis is most associated with the lungs, although it may also affect other regions of the body. Most infections are asymptomatic, which is known as latent TB. Roughly 10% of latent infections proceed to active illness, which kills about half of individuals afflicted if left untreated. A persistent cough with bloody sputum, fever, night sweats, and weight loss are all hallmark indications of active tuberculosis. Weight loss gave rise to the historical phrase "consumption." Other organ infections can generate a variety of symptoms.

The bacterium Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.

One of the primary drivers driving market growth is the high prevalence of TB in the region, as well as favourable health-care policies. According to the World Economic Forum, North America has a robust economy, accounting for 27.95% of global GDP, which is one of the elements influencing the healthcare sector. When comparing the two countries, the US spends more on healthcare than Canada. Additionally, the industry is being driven by greater rise in expenditure for private hospital care, physician, health insurance, and clinical services. Furthermore, the need for TB diagnosis tools and medicines is reflected in healthcare and public spending, which serves as a key driver for this market. Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread.

Market Dynamics

Industry Drivers

North America TB diagnostics market is mostly focused on those aged 60 and over, as this group is more susceptible to infectious infections. The growing geriatric population base, which is contributing to the global TB diagnostics market's growth.

To combat the spread of TB, private and public healthcare institutions are launching programmes. Increasing diagnosis and screening rates by raising knowledge about the importance of diagnosis is assisting the worldwide TB diagnostics market to expand at a significant rate over the forecast period.

The focus of development is on increasing screening rates, sophisticated techniques, diagnostic affordability, mortality reduction, and speedier clinical judgments. These approaches have resulted in higher rates of curative and preventative diagnosis. As a result, demand for diagnostic tests has increased, resulting in the worldwide North America TB diagnostics market expanding.

Industry Restraints

During the projection period, the high cost of testing techniques and the need for specialised instruments for testing are projected to limit the worldwide TB testing market's growth.

TB testing market is likely to be restrained in North America by compromised accuracy and longer processing times over the forecast period.

North America TB Diagnostics Market Segmentation Analysis

By Test Type

Nucleic Acid Testing (NAT) supports rapid identification of tuberculosis by detecting genetic material associated with the causative bacteria and is particularly valuable when faster diagnostic decisions are needed. Skin Test / Mantoux Test (TST) is commonly used to identify an immune response associated with TB infection and remains relevant for screening and assessment. Blood Test / Serology Test provides another approach for evaluating biological or immune responses and can be incorporated into diagnostic workflows depending on the clinical requirement. SMEAR Microscopy offers a relatively accessible laboratory method for examining samples for acid-fast bacilli and can provide preliminary evidence of infection. Cultured-Based Tests remain important for laboratory confirmation and detailed assessment, although they generally require more time than rapid molecular techniques. Radiography Tests, particularly chest imaging, help identify abnormalities that may indicate pulmonary TB and are often used together with laboratory testing. The Others category includes additional diagnostic methods and emerging technologies that support TB screening, detection, confirmation, and clinical evaluation.

Request Customizationto receive a tailored report.

By End-User

Hospitals and Diagnostic Laboratories are key end-users because they handle substantial volumes of TB screening and diagnostic procedures while providing access to laboratory infrastructure and multiple testing technologies. Physician’s Office Laboratories enable testing within outpatient healthcare settings, supporting convenient assessment and follow-up for patients. Reference Laboratories provide specialized diagnostic services and process samples received from healthcare facilities that may not have advanced testing capabilities in-house, making them important for complex or specialized TB investigations. Academics and Research Facilities contribute to the development, testing, and validation of new diagnostic approaches, biomarkers, molecular techniques, and other technologies. These facilities also support research aimed at improving diagnostic accuracy, reducing testing time, and expanding the practical use of TB detection methods.

Speak to an Analystto discuss market opportunities.

North America TB Diagnostics Market Regional Analysis

In 2020, North America had a market share of USD 0.56 billion in global tuberculosis (TB) diagnostics, which is expected to expand significantly through 2028. The economically stable and well-informed populace is responsible for the region's growth. The regional picture will be aided by a well-established healthcare system and extensive acceptance of technologically improved items.

North America is anticipated to be the largest market for TB diagnostics by 2030, with a market value of USD 905.08 million and a CAGR of 5.66%. The robust regional market may be attributed to the increased demand for sophisticated healthcare and the use of technology and novel tests for diagnosis, treatment, care, rehabilitation, and overall healthcare improvement. Increased research and development investment for better TB diagnostics is projected to boost the tuberculosis diagnostics market.

In 2020, the North American market was worth USD 0.56 billion. The adoption of comparably technologically advanced and high-cost healthcare solutions in major nations such as the United States and the highly knowledgeable and economically stable population in key countries such as the United States have given the area a robust share.

List of Key and Emerging Players in North America TB Diagnostics Market

• Danaher Corporation
• Thermo Fisher Scientific
• Abbott Laboratories
• Hologic, Inc.
• Oxford Immunotec